Background: Vascular endothelial cell activation and dysfunction is observed in patients
Introduction
Heart Failure is associated with the dysregulation of a number of neurohormonal systems including the adrenergic and renin-aldosterone-angiotensin system, the modulation of which form critical therapeutic strategies in the management of this syndrome. However none of the existing therapeutic regimens employed prevent the ultimate progression of the disease and the deterioration of left ventricular (LV) function suggesting that other systems are necessarily involved in this pathological process. Much of the current research aimed at elucidating the mechanisms of disease progression has focused on the involvement of proinflammatory cytokines and their potential as a therapeutic target in the treatment of heart failure. The cytokine theory of heart failure was born from the observation that expression of pro-inflammatory cytokines such as TNF and IL-6 are increased in both the myocardium and the circulation of heart failure patients and correlate with deteriorating functional status and disease progression (4, 5, 13, 20, 23, 39) . In addition, when expressed in sufficiently high concentrations known biological effects of these molecules can explain many aspects of the heart failure phenotype (6, 7, 22, 29, 38, 44). As such the syndrome of heart failure is generally considered to possess a clear inflammatory component that is of clinical significance not only locally in the myocardium but also systemically through the alteration of endothelial cell function thus contributing to the circulatory adaptations that occur during heart failure.
The activation of the innate immune system is thought to play a major role in heart failure.
Many tissues, including the heart and the vascular endothelium may contribute to the production of cytokines. We hypothesise that in addition to secretion of cytokines endothelial cells are also an important target of such and the inflammatory activation of these cells plays an important role in the progression of heart failure. Endothelial cells play a critical role in the control of vascular function. Under resting conditions the vascular endothelium functions to inhibit platelet aggregation, leukocyte activation and adhesion, prevents the proliferation of the underlying smooth muscle cells, prevents excessive deposition or degradation of matrix and regulates vascular tone and permeability.
Activation or injury to the endothelial cells by soluble factors in the circulation, interaction with activated blood cells, altered flow conditions and shear stress will change their function and alter the balance between the many countervailing forces they control to maintain homeostasis within the blood vessel.
Several studies have demonstrated that the serum of heart failure patients can alter the function of endothelial cells by down regulating the expression of endothelial nitric oxide synthase (eNOS) and inducing endothelial cell apoptosis in culture (2, 33) . Furthermore, using a novel endothelial cell biopsy technique Colombo et al recently demonstrated peripheral vein endothelial cell activation (inducible NOS (iNOS) and cyclo-oxygenase 2 (COX2) expression) and impaired endothelial cell function in patients with decompensated heart failure which subsides with a return to a clinically compensated state (9, 10). Indeed, impaired vascular endothelial function is associated with increased mortality risk in heart failure (21).
However, given the importance put upon the role of pro-inflammatory factors in the progression of heart failure little is known about the pro-inflammatory potential in the circulation of these patients with regard to the ability to activate pro-inflammatory pathways in endothelial cells. The aim of this study was to determine whether serum from patients with heart failure possess the bioactivity to activate inflammatory pathways in endothelial cells in culture using a bioassay based on the activation of the NF B pathway and induction of endogenous inflammatory gene expression. Although heart failure is a progressive disease a subset of patients, at a certain point in time, develop a very rapid progressive deterioration which requires inotropic support and emergency implantation of a LVAD. The cause of such is unknown. We hypothesise that changes in the balance between pro and anti-inflammatory cytokines could play an important role. . To clarify this we have compared these patients profile with end stage heart failure patients who are clinically stable.
Materials and methods

Study design
Two groups of heart failure patients were recruited to this study on the basis of the severity of disease and the operative treatment required for each (elective cardiac transplantation versus emergency LVAD implantation). Endothelial cell activation in response to treatment with the serum samples from these patients was investigated in an in vitro bioassay system by monitoring the ability of each sample to initiate the activation of NF B and to induce the expression of E-selectin in pulmonary artery endothelial cells. These cells were chosen because of their strategic location. It is likely that other types of endothelial cells will react in a similar fashion although endothelial cell function id known to be heterogeneous. In an attempt to identify the serum factors responsible for the observed bioactivity serum levels of individual pro-and anti-inflammatory cytokines were measured and antibody blocking studies were performed.
The protocol for this study was approved by the Royal Brompton and Harefield Research Ethics committee and informed consent was obtained from each patient.
LVAD Patients
The study included 14 consecutive patients undergoing emergency LVAD implantation because of deteriorating clinical status with evidence of secondary organ dysfunction in the context of low cardiac output and increased filling pressure despite appropriate medical treatment. All 14 patients were male. Mean age 38.0 ± 4.3 years. Diagnosis: dilated cardiomyopathy (11), ischaemic heart disease (1), ischaemic heart disease with post infarct ventricular septal defect rupture (2) . All patients were in NYHA Class IV and had deteriorated over a period of 2.3 ± 0.4 days. All patients were on inotropes and 8 were supported by intra-arterial balloon pump (IABP, Table1). Patients with histological evidence of myocardartis were excluded from the study. Blood was collected immediately prior to LVAD insertion, centrifuged at 2500rpm for 10 minutes and the resulting serum supernatants were stored at -40°C.
Heart Failure Patients
The study included 15 consecutive patients with stable advanced heart failure undergoing elective cardiac transplantation and not meeting our criteria for LVAD implantation. 13 patients were male and 2 were female. Mean age 45.3 ± 3.7 years. Diagnosis: dilated cardiomyopathy (8), ischaemic heart disease (6), post partum cardiomyopathy (1). 12 patients were in NYHA Class III and 3 in NYHA class IV. 3 patients were on inotropes and one was supported by IABP. Of the remaining patients 11 were receiving ACE inhibitor treatment and one the angiotensin receptor blocker Losartan (Table1). Patients with histological evidence of myocardartis were excluded from the study. Blood was collected at the time of cardiac transplantation, centrifuged at 2500rpm for 10 minutes and the resulting serum supernatants were stored at -40°C.
Cell culture
Human pulmonary artery endothelial cells (PAEC) were isolated from the pulmonary artery trimmings from heart and heart/lung donors. Cells were grown on 1% gelatin in M199 medium supplemented with penicillin (100units/ml), streptomycin (100µg/ml), L-glutamine (2mM), 25% heat-inactivated foetal bovine serum, 25mM HEPES and endothelial cell growth factor. For experiments cells were seeded into 24 well plates and allowed to grow to 80% confluence. Cells were incubated with M199 containing no additives for 24 hours prior to the start of each experiment to achieve a true resting state. Under these conditions, cellular I B protein levels were abundant, there was no evidence of nuclear NF B p65 (data not shown) and E-selectin expression remained low.
Bioassay
Influence of patients' serum on PAEC I B levels. I B levels in cultured PAEC were monitored in response to patient serum as a measure of the ability of inflammatory factors to activate NF B. PAEC were incubated with 10µM cycloheximide for 30 minutes prior to incubation with vehicle, recombinant TNF (rhTNF , 0.001-10ng/ml) or serum (diluted 1:1 in medium). For TNF neutralizing experiments the TNF neutralizing antibody (0.5µg/ml, R&D Systems) was added to the serum or cytokines and incubated at 37ºC for 30 minutes prior to addition to cells.
Following treatment cells were lysed in 1% SDS containing protease inhibitors. Proteins were resolved on 10% SDS-polyacrylamide gel by electrophoresis and transferred to nitrocellulose membrane. Proteins were detected using polyclonal anti-I B (0.2µg/ml, Santa Cruz (sc 371) or monoclonal anti--tubulin (clone TUB2.1, 1.8µg/ml, Sigma T4026) and relevant horseradish peroxidase-conjugated secondary antibody (Dakocytomation. P0448, P0260). Immunoreactive bands were visualised using Enhanced ChemiLuminescence (ECL™) detection system (Amersham Biosciences). Films were scanned using Biorad GS-710 densitometer and analysed using Biorad Quantity One software.
Influence of patients' serum on PAEC E-selectin Expression. E-selectin expression on PAEC was monitored in response to patient serum as a measure of induction of an NF B regulated endogenous gene. PAEC were incubated for 5hours with vehicle, rhTNF (0.001-10ng/ml) or patient serum (diluted 1:1 with medium). For anti-TNF and anti-IL-10 blocking studies, neutralizing antibody (anti-TNF 0.5µg/ml R&D Systems or anti-IL-10 1µg/ml, R&D Systems, MAB217) was added to the serum or cytokines and incubated at 37ºC for 30 minutes prior to addition to cells. Following treatment cells were trypsinised and E-selectin expression determined by flow cytometry using anti-E-selectin antibody (2µg/ml, clone BBIG-E5, R&D Systems, BBA21) and FITCconjugated secondary antibody (Dakocytomation, F0313). Log fluorescence intensity was measured and gates set at 2% positive cells on isotype control.
Analysis of Serum Cytokines Concentrations
Serum cytokine levels were measured using commercially available immunoassays (R&D Systems).
Statistical Analysis
Results involving patient samples did not pass normality and/or equal variance testing and thus the data can not be assumed to be normally distributed. These results are therefore expressed as median values with ranges. Differences between groups are assessed using percentiles. For Bioassay data, at least three independent assays, using pulmonary artery endothelial cell isolates from different sources, were performed for each patient sample and the mean response for each sample was used for grouped comparisons.
All other data pass normality and equal variance tests and are expressed as mean ± standard error of the mean. Differences between groups are assessed using ANOVA with post hoc ttest where required. Experiments were performed on at least three independent occasions using different pulmonary artery endothelial cell isolates.
Correlations between parameters are analysed using Spearmans rank order correlation. p value <0.05 was considered significant.
Results
Effect of patient serum on endothelial cells I B levels
Control AB serum had no significant effect of PAEC I B levels (94.1 ± 21.0 % of control levels) whilst 30 minutes treatment of these cells with increasing concentrations of TNF
(1 pg/ml -10ng/ml) induced a concentration dependant reduction in the level of I B protein in these cells which was significant at 10pg/ml (51.0 ± 6.0% of control levels, p<0.05, n=7, Figure 1a ).
Compared to the AB serum control, incubation of PAEC with patient serum for 60 minutes induce a significant degradation of I B the remaining levels of which were similar to those following treatment with TNF (10pg/ml). I B levels in PAEC were reduced to 42.2 (27.8-74.4) % of that in control cells following treatment with Tx patient serum (n=10, p<0.05) and to 35.7 (31.6-72.8) % following treatment with serum from LVAD patients (n=10, p<0.05). There was no significant difference between the extent of I B degradation induced by either Tx or LVAD patient serum (p=0.623, figure 1b and c).
Effect of patient serum on endothelial cell E-selectin expression
Treatment of the PAEC with control AB serum had no significant effect on E-selectin expression (3.8 ± 0.4% positive cells (n=8) versus 3.3 ± 0.3% in control resting cells (n=19, p=0.391).
Treatment of PAEC with Tx patient serum caused a small but significant increase in Eselectin expression (5.6 (3.2-9.4) % positive cells, p<0.05, n=15) above control levels (2.9 (2.1 -7.7) % positive cells). There was, however, no significant increase in E-selectin expression above control levels following incubation of the cells with LVAD patient serum 
Cytokines
Similar to other studies TNF levels were found to be increased in the circulation of the severely deteriorating LVAD patients (8.5 (4.1 -32.9) pg/ml, n=14) compared to the patients with less severe heart failure undergoing cardiac transplantation (3.6 (1.8 -7.8) pg/ml, n=15, p<0.05, figure3a). figure 3c ).
Circulating IL-1 levels were low in all patients and not significantly different between the two groups (p=0.964, figure 3d ).
Serum IL-10 levels were significantly higher in LVAD patients (12.1 (0.0-85.9) pg/ml, n=14) compared to Tx patients (1.7 (0.0-30.4) pg/ml, n=12, p=0.016, figure 3e). Serum IL-6 was significantly higher in LVAD (91.0 (6.3-129.8) pg/ml, n=14) compared to Tx patients (3.6 (0.7-15.6) pg/ml, n=12, p<0.001, Fig.3f ).
Investigation into the involvement of TNF in the observed bioactivity
To investigate the potential importance of TNF in the observed pro-inflammatory bioactivity of the serum the bioassays were performed in the presence of anti-TNF In agreement with this result there was no significant correlation between TNF levels or sTNFR/TNF molar ratios and bioactivity to induce I B depletion or increased E-selectin expression in either group of patients (p>0.05).
Involvement of IL-10 in the observed bioassay.
There was a significant negative correlation between bioactivity to induce E-selectin expression and serum IL-10 concentrations (R 2 =0.432, p<0.001).
To explore the influence of IL-10 on E-selectin expression the bioassay experiments were carried out in the presence of anti-IL-10 neutralising antibodies. Under conditions that specifically attenuated IL-10 (50ng/ml)-induced signaling events (JAK1 and STAT1 phosphorylation), in a responsive cell line (U937, figure 6a and b), neutralising IL-10 failed to alter the bioactivity of either Tx or LVAD serum with respect to E-selectin induction in PAEC (5.2 (2.9-6.8) % and 3.1 (1.8-6.1) % positive cells, respectively, figure 6c) .
Discussion
This study has demonstrated that the serum of patients with end stage heart failure does The identity of the NF B activating bioactivity in the circulation of these heart failure patients is at present unclear. The pro-inflammatory cytokine TNF is a tempting candidate since it is a strong inducer of NF B activity in cultured endothelial cells ( figure 3 ) and increased levels have been demonstrated in the circulation of heart failure patients in this and other studies (4, 5, 13, 20, 23, 39) . However further investigations into the contribution of TNF to this inflammatory bioactivity of heart failure patients' serum revealed that it is unlikely to be involved. Firstly, the level of I B degradation induced by treatment of the endothelial cells with serum of both groups of patients were similar despite the concentration of TNF being higher in the decompensated LVAD patients. Secondly, any effect of TNF must take place in the context of simultaneously present factors that may either enhance or inhibit its biological effect. In this regard circulating levels of sTNFR in both groups of patients were increased compared to normal levels (1) and the high molar excess of sTNFR to TNF in all these patients suggests that the biological activity of TNF may be effectively neutralized (15, 18, 40) . This theory was strengthened by TNF blocking studies which failed to alter the bioactivity of the serum to induce I B degradation. This negative finding regarding the influence of serum TNF in heart failure patients on NF B activation is supported by a recent study by Frantz et al (17) who demonstrated that increased NF B activation in the myocytes, endothelial cells and infiltrating leucocytes in the failing myocardium also did not correlate with TNF levels.
Taken together these data suggest that factors other than TNF are important with regard to the activation of NF B in the setting of heart failure and further studies are required to identify them. In this study we identified IL-10 as a potential candidate responsible for this antiinflammatory activity. IL-10 expression has been previously observed in heart failure patients (43) and serum levels measured in this current study were increased in the LVAD patients compared to the Tx patients and correlated with reduced bioactivity of the serum to induce E-selectin expression. IL-10 has been shown to inhibit NF B DNA binding activity in a number of cell culture systems (36) however, data regarding the effects of IL-10 on inflammatory mechanisms in endothelial cells are limited and somewhat conflicting (24, 27, 30, 37, 42). In this present study we further investigated the possibility that increased IL-10 levels were influencing the E-selectin bioassay system with the use of anti-IL-10 neutralising antibodies. The E-selectin response of the endothelial cells to serum was not altered by the presence of IL-10 neutralising antibodies suggesting that unidentified factors present in the serum of the LVAD patients are responsible for the observed antiinflammatory activity and the absence of E-selectin gene induction.
This data must also be considered in view of the medical treatment the patients were receiving. The inotropic agents, in particular the phosphodiesterase III inhibitors, used to treat the LVAD patients could directly influence the serum bioactivity to induce NF B activation and E-selectin expression. These agents increase intracellular levels of cAMP by inhibiting its breakdown. Early studies demonstrated that increasing intracellular cAMP with pharmacological agents could inhibit cytokine-induced expression of a number NF B responsive genes in HUVEC including E-selectin (16, 19, 28, 32) . Importantly, increased intracellular cAMP had no effect on NF B nuclear translocation but inhibited its transcriptional activity through CREB successfully out competing NF B for binding to limited amounts of CBP (31). Taken together this evidence provides a possible explanation for the dissociation between the bioactivity of serum to induce I B degradation and that to induce E-selectin expression in the LVAD patients, all of whom were receiving such inotropic therapy. However, further analysis in this regard is severely hindered by the use multiple combinations of such drugs on a relatively small number of patients and a dedicated follow-up study is needed to specifically address this issue.
In conclusion this study has demonstrated that although pro-inflammatory cytokine expression is increased in the circulation of deteriorating advanced heart failure patients the consequences of such can not be predicted when individual factors are viewed in isolation since there is also an increase in counteracting anti-inflammatory factors able to prevent some specific inflammatory events in peripheral endothelial cells. To the extent that this in vitro data may be extrapolated to the in vivo situation increased TNF and NF B activation in the setting of heart failure may not be adversely contributing to the pathology of heart failure and the rapid deterioration of the LVAD patients by pro-inflammatory mechanisms. Given that trials of anti-TNF and anti-inflammatory strategies in the treatment of heart failure have been largely unsuccessful (3, 8, 12 , 25) future therapeutic strategies for the treatment of this syndrome may be of greater benefit when aimed at specific cellular events rather than the actions of single molecules or a generalized antiinflammatory approach. Summary graph of grouped data demonstrating the bioactivity of heart failure patients' serum to induce E-selectin expression on PAEC in culture compared to the effects of low concentrations of TNF and control AB serum. * p<0.05 from control untreated cells. TNF 1.98pg/ml, IL-1 <3.9pg/ml, sTNFR1 914pg/ml, sTNFR2 1500 pg/ml, IL-10 <7.8pg/ml, IL-6 1.49 pg/ml). Table 2 
